191 results about "Conjugated polyene" patented technology

The crosslinkable rubber composition of the invention is crosslinkable by hot air, and a hot-air crosslinked rubber sheet thereof has no scratch on the surface in a hardness test using a pencil of HB and has a compression set of not more than 70% after a heat treatment at 150° C. for 22 hours. The rubber composition comprises an ethylene/α-olefin/non-conjugated polyene random copolymer rubber comprising a specific vinyl end group-containing norbornene compound, a SiH group-containing compound having at least two SiH groups in one molecule, and if necessary, an addition reaction catalyst comprising a platinum group element and a reaction inhibitor. The automobile weatherstrip, hose, rubber vibration insulator, belt, sealing material, expanded product, covered electric wire, electric wire joint, electric insulating part and household rubber product according to the invention comprise the above-mentioned rubber composition. The rubber composition has a high crosslinking rate and excellent productivity to produce crosslinked rubber molded products, is capable of undergoing hot-air crosslinking such as HAV or UHF and is capable of providing crosslinked rubber molded products having excellent compression set resistance, strength properties, heat resistance, weathering resistance and abrasion resistance.

The crosslinkable rubber composition is crosslinkable at room temperature, has a gelation time at room temperature of 30 days or less, and can prepare a crosslinked rubber sheet by crosslinking the composition at room temperature, wherein the crosslinked rubber sheet has a tensile elongation of 20% or more, and is free of cracks after treatment at 40° C. in a 50 pphm ozone concentration for 96 hr. Specifically, it comprises an ethylene/alpha-olefin/non-conjugated polyene random copolymer rubber comprising a norbornene compound having a specific vinyl end group, an SiH group-containing compound, which has at least two SiH groups in one molecule, and optionally a platinum catalyst, a reaction inhibitor and/or a silane-coupling agent. The sealing, potting and coating materials and adhesives of the present invention comprise the above rubber composition. The rubber composition has a high crosslinking rate at room temperature and excellent productivity, and can prepare crosslinked rubber molded products (including foamed products) having excellent weathering resistance, ozone resistance, heat aging resistance and compression set at low cost. Further, it is suitable for use of electric and electronic parts, transportation machines, civil engineering and construction materials, medical appliances and goods for leisure activities.

To provide a resin composition including: an ethylene-vinyl alcohol copolymer (A) having an ethylene content of from 15 to 65 mol % and a saponification degree of at least 95 mol %, a phosphoric acid salt (B) which can form a hydrate, and a conjugated polyene compound (C) having a boiling point of at least 150° C., wherein the resin composition comprises from 50 to 99 parts by weight of (A), from 1 to 50 parts by weight of (B) and from 0.00001 to 1 parts by weight of (C), based on 100 parts by weight of the total amounts of (A) and (B). This resin composition excels in gas barrier property and also in moisture resistance at high temperatures and high humidities. Therefore, it is suitable for food packaging containers to be retorted.

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

The present invention provides a 4-methyl-1-pentene/α-olefin copolymer being excellent in lightness, stress absorption, stress relaxation, vibration damping properties, scratch resistance, abrasion resistance, toughness, mechanical properties and flexibility, having no stickiness during molding operation and being excellent in the balance among these properties; a composition comprising the polymer; and uses thereof. The 4-methyl-1-pentene/α-olefin copolymer (A) of the present invention satisfies specific requirements, and comprises 5 to 95 mol % of a structural unit (i) derived from 4-methyl-1-pentene, 5 to 95 mol % of a structural unit (ii) derived from at least one kind of α-olefin selected from α-olefins having 2 to 20 carbon atoms excluding 4-methyl-1-pentene and 0 to 10 mol % of a structural unit (iii) derived from a non-conjugated polyene, provided that the total of the structural units (i), (ii), and (iii) is 100 mol %.

A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

A method of treating liver disease in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.

A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

A rubber composition which is crosslinkable with hot air or a hot press and gives a hot-air-crosslinked rubber sheet which receives no scratch on the surface in an HB pencil hardness test and has a compression set of 70% or lower through 22-hour heat treatment at 150 DEG C. The composition comprises: an ethylene/ alpha -olefin/unconjugated polyene random copolymer rubber wherein the unconjugated polyene is a specific norbornene compound terminated by a vinyl group; and a compound having two or more SiH groups per molecule. It may optionally contain an addition reaction catalyst comprising a platinum-group metal and a reaction inhibitor.

A rubber composition for fuel cell seals, HDD top cover gaskets or cable connector seals is disclosed. The rubber composition comprises a specific ethylene/α-olefin/non-conjugated polyene copolymer [A], a specific organopolysiloxane [B] and an SiH group-containing compound [C], with the weight ratio of [A]:[B] being 100:0 to 5:95. A fuel cell sealing material, HDD top cover gasket material, cable connector sealing material, fuel cell seal, HDD top cover gasket and cable connector seal according to the present invention comprise the composition. A fuel cell according to the present invention includes the fuel cell seal. A hard disk drive of the present invention includes the gasket. An automotive cable connector according to the present invention is sealed by the composition. The invention provides a crosslinkable rubber composition that has good high-speed moldability and can give fuel cell seals excellent in resistances to heat, acids and gas permeation. Further provided are a fuel cell seal from the composition, a fuel cell sealing material comprising the composition, and a fuel cell including the seal. The present invention also provides a crosslinkable rubber composition that has good high-speed moldability and can give HDD top cover gaskets having low hardness and being excellent in heat resistance, compression set resistance and long-term sealing properties. Further provided are a gasket from the composition, a HDD top cover gasket material comprising the composition, and a hard disk drive including the gasket. The present invention also provides a crosslinkable rubber composition that has excellent sealing properties and insertion properties with respect to cables without oil bleeding. Further provided are a cable connector seal from the composition, a cable connector sealing material comprising the composition, and an automotive cable connector including the seal.

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.

A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

A solar-cell sealant that has excellent properties such as transparency, flexibility, adhesiveness, heat resistance, appearance, cross-linking characteristics, electrical characteristics, and calenderability. A solar-cell sealant that contains an ethylene/α-olefin/unconjugated-polyene copolymer satisfying requirements (a1) through (a3). Requirement (a1) is that constituent units derived from ethylene constitute 80-90 mol %, constituent units derived from C3-20 α-olefin constitute 9.99-19.99 mol %, and constituent units derived from an unconjugated polyene constitute 0.01-5.0 mol % of said copolymer. Requirement (a2) is that the MFR of said copolymer, as measured in accordance with ASTM D1238 at 190° C. under a 2.16 kg load, be at least 2 g/10 min. and less than 10 g/10 min. Requirement (a3) is that the Shore A hardness of said copolymer, as measured in accordance with ASTM D2240, be 60 to 85.